Cargando…

IMMU-06. DELTA-24-RGD EXPRESSING POSITIVE IMMUNE MODULATORS SHOW ANTI-DIPG EFFECT AND INCREASE TUMOR IMMUNE INFILTRATION

Diffuse Intrinsic Pontine Gliomas (DIPG) are aggressive pediatric brain tumors that arise in the pons of children, being the leading cause of pediatric death caused by cancer. We have previously demonstrated that Delta-24-RGD administration is safe and efficacious in DIPG preclinical models, indicat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laspidea, Virginia, Gupta, Sumit, Puigdelloses, Montserrat, Labiano, Sara, Ausejo-Mauleon, Iker, de la Nava, Daniel, Becher, Oren J, Gumin, Joy, Fueyo, Juan, Gomez-Manzano, Candelaria, Alonso, Marta M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Immunology/Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168174/ http://dx.doi.org/10.1093/neuonc/noab090.114

Ejemplares similares

IMMU-01. THE ONCOLYTIC VIRUS DELTA-24-RGD IN COMBINATION WITH AN AGONISTIC CD40 MAB INDUCES A DURABLE AND SYNERGISTIC ANTI-TUMOR IMMUNE EFFECT IN DIPG PRECLINICAL MODELS
por: Labiano, Sara, et al.
Publicado: (2021)

IMMU-08. MICROENVIRONMENT MODULATION BY TIM-3 BLOCKADE IMPROVES THE OUTCOME OF PRECLINICAL DIPG MODELS
por: Ausejo-Mauleon, Iker, et al.
Publicado: (2021)

IMMU-18. Targeting Antigen Presenting Cells to improve virotherapy efficacy in Diffuse Midline Gliomas
por: Labiano, Sara, et al.
Publicado: (2022)

IMMU-09. MODULATING THE MYELOID POPULATION IN DIPG MODELS WITH ONCOLYTIC VIRUS AND COMPLEMENT INHIBITORS SHOWS THERAPEUTIC EFFICACY
por: Puigdelloses, Montserrat, et al.
Publicado: (2021)

THER-01. AWAKING THE IMMUNE SYSTEM WITH AN IMMUNO-ONCOLYTIC VIRUS AS A THERAPEUTIC STRATEGY FOR DIPGs
por: Laspidea, Virginia, et al.
Publicado: (2020)

DIPG-10. DELTA-24-RGDOX PROMOTES ANTITUMOR IMMUNE RESPONSE IN DMG MODELS
por: Laspidea, Virginia, et al.
Publicado: (2023)

IMMU-06. Landscape of adaptive immunity of childhood brain cancers
por: Raphael, Itay, et al.
Publicado: (2022)

CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models
por: Puigdelloses, Montserrat, et al.
Publicado: (2021)

Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory
por: Martinez-Velez, Naiara, et al.
Publicado: (2022)

IMMU-11. LOCOREGIONAL DELIVERY OF TRANSIENT GD2 CAR T CELLS FOR SAFE AND EFFECTIVE TREATMENT OF DIPG
por: Foster, Jessica, et al.
Publicado: (2020)

DIPG-04. TUMOR CELL-INTRINSIC TIM-3 PROMOTES DIFFUSE INTRINSIC PONTINE GLIOMA TUMORIGENESIS
por: Ausejo-Mauleon, Iker, et al.
Publicado: (2023)

Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas
por: Laspidea, Virginia, et al.
Publicado: (2022)

HGG-15. THE IMIPRIDONE ONC201 IN COMBINATION WITH THE ONCOLYTIC ADENOVIRUS DELTA-24-RGD HAS A SYNERGISTIC EFFECT IN PRECLINICAL MODELS OF PHGGS AND DMGS
por: de la Nava, Daniel, et al.
Publicado: (2021)

IMMU-27. ANALYSIS OF IMMUNE SIGNATURES IN PEDIATRIC GLIOBLASTOMAS FOR PATIENT STRATIFICATION TO IMMUNOTHERAPY
por: Chandramohan, Vidyalakshmi, et al.
Publicado: (2020)

IMMU-11. CLINICAL UPDATES AND CORRELATIVE FINDINGS FROM THE FIRST PATIENT WITH DIPG TREATED WITH INTRACRANIAL CAR T CELLS
por: Vitanza, Nicholas, et al.
Publicado: (2021)

IMMU-29. AIF1 IS A PROGNOSTIC BIOMARKER AND CORRELATED WITH IMMUNE INFILTRATES IN GLIOMAS
por: Chai, Yi, et al.
Publicado: (2020)

IMMU-14. SynNotch chimeric antigen receptor (CAR) T-cells as a potential treatment for diffuse intrinsic pontine glioma (DIPG)/diffuse midline glioma (DMG)
por: Ferrerosa, Lauren, et al.
Publicado: (2022)

IMMU-01. IMMUNE CHECKPOINT INHIBITION FOR PEDIATRIC CNS TUMORS: A SINGLE INSTITUTION EXPERIENCE
por: Cacciotti, Chantel, et al.
Publicado: (2020)

IMMU-28. IMMUNOGENOMIC ANALYSIS REVEALS LGALS1 CONTRIBUTES TO THE IMMUNE HETEROGENEITY AND IMMUNOSUPPRESSION IN GLIOMA
por: Chen, Qun, et al.
Publicado: (2020)

IMMU-06. T-CELL IMMUNOTHERAPY FOR PEDIATRIC BRAIN TUMORS: DIVERSITY IN CELL SURFACE ANTIGEN AND HLA EXPRESSION NECESSITATES A MULTI-PRONGED APPROACH
por: Houke, Haley, et al.
Publicado: (2020)

The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models
por: Martínez-Vélez, Naiara, et al.
Publicado: (2019)

IMMU-17. CAR T CELLS TARGETING THE INTEGRIN ALPHA(V)BETA(3) EXHIBIT ROBUST ANTI-TUMOR RESPONSES AGAINST DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND GLIOBLASTOMA (GBM)
por: Cobb, Dustin, et al.
Publicado: (2020)

IMMU-03. CHARACTERIZING THE IMMUNE MICROENVIRONMENT OF PEDIATRIC BRAIN TUMORS
por: Galvin, Robert, et al.
Publicado: (2021)

IMMU-22. PHASE IB IMMUNOTHERAPY CLINICAL TRIAL WITH THE USE OF AUTOLOGOUS DENDRITIC CELLS PULSED WITH AN ALLOGENIC TUMORAL CELL LINES LYSATE IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Madrid, Andres Morales La, et al.
Publicado: (2020)

IMMU-20. EVALUATION OF CAR T CELLS IN EPENDYMOMA
por: Nellan, Anandani, et al.
Publicado: (2020)

IMMU-14. IMMUNE CHECKPOINT INHIBITOR THERAPY FOR TREATMENT OF SYNCHRONOUS CANCERS IN PAEDIATRIC PATIENTS WITH CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY
por: Henderson, Jacob, et al.
Publicado: (2020)

IMMU-03. UPDATES ON BRAINCHILD-01, -02, AND -03: PHASE 1 LOCOREGIONAL CAR T CELL TRIALS TARGETING HER2, EGFR, AND B7-H3 FOR CHILDREN WITH RECURRENT CNS TUMORS AND DIPG
por: Vitanza, Nicholas, et al.
Publicado: (2020)

IMMU-18. FAVORABLE OUTCOME IN REPLICATION REPAIR DEFICIENT HYPERMUTANT BRAIN TUMORS TO IMMUNE CHECKPOINT INHIBITION: AN INTERNATIONAL RRD CONSORTIUM REGISTRY STUDY
por: Bouffet, Eric, et al.
Publicado: (2020)

IMMU-07. IMMUNE EFFECTOR CELL ASSOCIATED NEUROTOXICITY (ICANS) AMONG PEDIATRIC AND AYA PATIENTS: MD ANDERSON CANCER CENTER EXPERIENCE
por: Brown, Brandon, et al.
Publicado: (2020)

IMMU-16. INTRA-TUMOURAL IL-12 DELIVERY ENABLES CAR T-CELL IMMUNOTHERAPY FOR HIGH-GRADE GLIOMA
por: Agliardi, Giulia, et al.
Publicado: (2020)

IMMU-02. Targeted innovative antibody fragment-based immunotherapy for medulloblastoma
por: Niesen, Judith, et al.
Publicado: (2022)

IMMU-14. COMPUTATIONAL DECONVOLUTION OF TUMOR-INFILTRATING IMMUNE COMPONENTS IN PEDIATRIC NERVOUS SYSTEM TUMORS
por: Beck, Pengbo, et al.
Publicado: (2021)

IMMU-09. NIVOLUMAB THERAPY FOR A PEDIATRIC-ONSET PRIMARY INTRACRANIAL MELANOMA
por: Oba, Utako, et al.
Publicado: (2020)

IMMU-20. Effective CAR-T cell medulloblastoma therapy in an immunocompetent mouse model
por: Tsahouridis, Rania, et al.
Publicado: (2022)

IMMU-17. Comprehensive immunological gene expression profiling of pediatric brain tumors
por: Levine, Adrian, et al.
Publicado: (2022)

IMMU-06. SYSTEMIC MRNA VACCINES RESET IMMUNOGENICITY AGAINST DIFFUSE MIDLINE GLIOMA
por: McGuiness, James, et al.
Publicado: (2023)

IMMU-05. B7-H3-SPECIFIC CAR T CELLS HAVE POTENT ANTI-TUMOR ACTIVITY IN THE GL261 IMMUNE-COMPETENT MURINE BRAIN TUMOR MODEL
por: Haydar, Dalia, et al.
Publicado: (2020)

IMMU-15. PROTEOGENOMIC DISCOVERY OF NOVEL TUMOR PEPTIDES AS NEOANTIGENS FOR PERSONALIZED T CELL IMMUNOTHERAPY IN MEDULLOBLASTOMA
por: Rivero-Hinojosa, Samuel, et al.
Publicado: (2020)

IMMU-10. TUMOR ASSOCIATED MYELOID CELLS DRIVE THE IMMUNOBIOLOGY OF HIGH RISK PEDIATRIC EPENDYMOMA
por: Griesinger, Andrea, et al.
Publicado: (2022)

IMMU-05. Integrative transcriptomic analysis of pilocytic astrocytomas reveals CNS region-associated characteristics
por: Rozowsky, Jacob S, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u4dlv999o1qaa90kutk03i1bs5